SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 47 filers reported holding SUNESIS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.57 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $13,000 | -35.0% | 48,707 | 0.0% | 0.00% | -50.0% |
| Q1 2020 | $20,000 | +25.0% | 48,707 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $16,000 | -54.3% | 48,707 | 0.0% | 0.00% | -66.7% |
| Q3 2019 | $35,000 | 0.0% | 48,707 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $35,000 | -40.7% | 48,707 | 0.0% | 0.00% | -50.0% |
| Q1 2019 | $59,000 | +195.0% | 48,707 | 0.0% | 0.01% | +100.0% |
| Q4 2018 | $20,000 | -80.0% | 48,707 | -3.0% | 0.00% | -70.0% |
| Q3 2018 | $100,000 | -5.7% | 50,209 | 0.0% | 0.01% | +11.1% |
| Q2 2018 | $106,000 | -22.6% | 50,209 | 0.0% | 0.01% | -43.8% |
| Q1 2018 | $137,000 | -4.9% | 50,209 | +29.0% | 0.02% | -23.8% |
| Q4 2017 | $144,000 | +128.6% | 38,930 | +19.4% | 0.02% | +110.0% |
| Q3 2017 | $63,000 | -28.4% | 32,613 | 0.0% | 0.01% | -44.4% |
| Q2 2017 | $88,000 | +8.6% | 32,613 | +64.2% | 0.02% | +20.0% |
| Q1 2017 | $81,000 | +12.5% | 19,857 | 0.0% | 0.02% | -6.2% |
| Q4 2016 | $72,000 | +2.9% | 19,857 | +24.1% | 0.02% | +6.7% |
| Q3 2016 | $70,000 | – | 15,999 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 2,600,000 | $1,092,000 | 1.15% |
| BVF INC/IL | 2,287,860 | $951,000 | 0.12% |
| Eventide Asset Management | 2,265,455 | $942,000 | 0.04% |
| SABBY MANAGEMENT, LLC | 400,140 | $166,000 | 0.04% |
| RP Management, LLC | 129,517 | $54,000 | 0.04% |
| Palo Alto Investors LP | 1,162,473 | $483,000 | 0.03% |
| NEA Management Company, LLC | 1,298,274 | $539,000 | 0.02% |
| Rhenman & Partners Asset Management AB | 377,244 | $157,000 | 0.02% |
| GREAT POINT PARTNERS LLC | 317,962 | $132,000 | 0.02% |
| Vivo Capital, LLC | 195,474 | $81,000 | 0.01% |